Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Medical Tech Outlook
![]()
Our autologous cell therapy leverages the “power” of patients’ own cells to restore cartilage tissue
Share this Article:
Tweet
|
Company
Co.Don
Headquarters
Berlin, Germany
Management
Ralf M. Jakobs, CEO and Tilmann Bur, COO
Description
Develops, produces, and markets a treatment for cartilage defects in the knee—the 100 percent autologous cell therapies for the repair of cartilage defects. The company leverages matrix-associated autologous cartilage cell transplantation (M-ACT) as a minimally-invasive treatment of articular cartilage damage. The autologous production of three-dimensional cartilage tissue without the use of foreign materials offers the formation of pressure-stable articular cartilage, which actively integrates into the surrounding tissue.The CO.DON group holds marketing authorizations for their product in the EU and Switzerland